Endocrine‐paracrine cells of the prostate (also known as APUD or neuroendocrine cells)
constitute, in addition to the basal and exocrine secretory cells, a third population of highly …

BACKGROUND Information is presented on prostatic neuroendocrine cells and
neuroendocrine differentiation in prostatic carcinoma. The prognostic and therapeutic …

Bombesin-like peptides such as gastrin-releasing peptide (GRP) have been shown to play a
role in cancer as autocrine growth factors that stimulate tumor growth through specific …

PURPOSE: To determine the activity and toxicity of doxorubicin in combination with cisplatin
and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize …

The prognostic significance of neuroendocrine differentiation in prostatic malignancy is
controversial, but the results of recent studies with markers such as chromogranin A and …

Over the last two decades, several lines of experimental evidence have suggested that the
gastrin-releasing peptide (GRP) may act as a growth factor in many types of cancer. For that …

An androgen-repressed human prostate cancer cell line, ARCaP, was established and
characterized. This cell line was derived from the ascites fluid of a patient with advanced …

Over the past 20 years, abundant evidence has been collected to suggest that gastrin-
releasing peptide (GRP) and its receptors play an important role in the development of a …

Demobesin 1 is a potent new GRP-R-selective bombesin (BN) analogue containing an open
chain tetraamine chelator for stable technetium-99m binding. Following a convenient …

Abstract Neutral endopeptidase 24.11 (NEP) is a cell-surface enzyme expressed by
prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the growth …